Sarepta Therapeutics Inc.

Duchenne Muscular Dystrophy

Duchenne muscular dystrophy is a major therapeutic focus, including studies in ambulatory and non-ambulatory populations and in patients with genotypes amenable to exon skipping approaches. The research portfolio includes work on eteplirsen, vesleteplirsen, and delandistrogene moxeparvovec for muscle function, dystrophin expression, and long-term safety.

  • Duchenne muscular dystrophy (DMD)
  • Exon 45 skipping and exon 53 skipping
  • Dystrophin restoration
  • Motor function and ambulation

Clinical activity also includes follow-up and treatment evaluation in patients with pre-existing AAV antibodies, reflecting interest in gene transfer therapy for broader DMD populations.

Limb-Girdle Muscular Dystrophy

Research in limb-girdle muscular dystrophy centers on LGMD2E/R4, also known as β-sarcoglycanopathy, with attention to gene delivery and restoration of β-sarcoglycan expression in skeletal muscle.

  • LGMD2E/R4
  • β-sarcoglycanopathy
  • β-sarcoglycan expression
  • Skeletal muscle gene delivery

The portfolio reflects a focus on inherited muscle disease subtypes with distinct molecular defects and measurable protein replacement endpoints.

Facioscapulohumeral Muscular Dystrophy

In facioscapulohumeral muscular dystrophy, the sponsor supports research targeting FSHD type 1 with emphasis on DUX4-related disease biology and treatment effects on muscle performance.

  • FSHD1
  • DUX4 inhibition
  • Upper limb function
  • Muscle weakness

These studies address a neuromuscular disorder with prominent involvement of shoulder girdle and upper extremity muscles.

Myotonic Dystrophy Type 1

Clinical research in type 1 myotonic dystrophy focuses on ARO-DM1 and the underlying molecular mechanisms associated with disease expression, with evaluation of safety, tolerability, and effects on the disorder’s neuromuscular manifestations.

  • Myotonic dystrophy type 1 (DM1)
  • RNA-targeted therapy
  • Neuromuscular impairment
  • Pharmacodynamics

This area extends the sponsor’s interest beyond dystrophinopathies into multisystem inherited muscle disease.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study of ADS-010 for Adults with Facioscapulohumeral Muscular Dystrophy Type 1

    Recruiting

    2 1 1
    Investigated drugs:
    Germany Italy The Netherlands Spain
  • Long-term Safety Study of Delandistrogene Moxeparvovec for Patients with Duchenne Muscular Dystrophy Who Previously Received SRP-9001

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Germany Italy Spain
  • A study testing the safety and effects of ADS-019 in adults aged 18 to 65 years with type 1 myotonic dystrophy

    Not yet recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Belgium Germany Italy Spain
  • Study on the Safety and Effectiveness of Delandistrogene Moxeparvovec for Patients with Duchenne Muscular Dystrophy

    Not yet recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Italy Spain Sweden
  • Study on the Effects of Casimersen and Golodirsen for Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping

    Not recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Czechia Denmark Hungary Ireland +3
  • Study on the Safety and Efficacy of Delandistrogene Moxeparvovec and Imlifidase for Patients with Duchenne Muscular Dystrophy with Pre-existing Antibodies

    Not recruiting

    1 1 1 1
    Spain